PharmaFocus Today – Page 66 – media

Pfizer’s pan-KRAS inhibitor cancer drug approved for clinical trials

On February 17, the CDE official website announced that Pfizer’s Class 1 new drug “PF-07934040 Tablets” has obtained implicit approval for clinical trials and is intended to be developed to treat advanced solid tumors carrying KRAS mutations. PF-07934040 is a pan-KRAS inhibitor under development and is currently undergoing Phase 1 clinical trials internationally. According to Yaozhi data, this is the first time that the product has been approved for IND in China. According to Pfizer’s official website, PF-07934040 is a pan-KRAS “ON/OFF” inhibitor that has activity against wild-type (wt) KRAS and major mutant subtypes, and is inactive against NRAS or HRAS. PF-07934040 has been shown to bind to both the OFF (GDP-bound) and ON (GTP-loaded) states of KRAS wt, and has very low binding affinity to mutants, with a selectivity for binding to KRAS that is 5,000 times higher than HRAS/NRAS. https://news.yaozh.com/archive/45010.html
- Source: drugdu
- 255
- February 24, 2025
First Pharmaceutical plans to increase the guarantee limit for its loss making subsidiary

Recently, the “time-honored” pharmaceutical distribution enterprise in Shanghai, First Pharmaceutical (600833. SH), announced the expected guarantee amount for its wholly-owned subsidiary in 2025. To support the operation and development of its wholly-owned subsidiaries, First Pharma plans to provide an additional guarantee limit of no more than RMB 210 million for three wholly-owned subsidiaries: First Pharma (Hong Kong) Limited (hereinafter referred to as “First Pharma Hong Kong”), Shanghai HSBC Pharmaceutical Materials Co., Ltd. (hereinafter referred to as “HSBC Pharma”), and Shanghai First Pharmaceutical Store Chain Operation Co., Ltd. (hereinafter referred to as “First Pharma Chain”). The above matters will be submitted to the shareholders’ meeting for deliberation on February 27, 2025. According to the arrangement, the newly added guarantee amounts for Yiyi Hong Kong, HSBC Pharmaceuticals, and Yiyi Chain are 60 million yuan, 100 million yuan, and 50 million yuan respectively, accounting for 20.97% of the latest net assets of ...
- Source: drugdu
- 134
- February 22, 2025
supports the introduction of original drugs for domestic production; National Healthcare Security Administration

NO.1 National Medical Products Administration: Support the introduction of original drugs for domestic production On February 20, according to the WeChat official account of the State Food and Drug Administration, Huang Guo, the deputy director of the State Food and Drug Administration, recently led a team to Shandong for research. Huang Guo emphasized that the National Medical Products Administration attaches great importance to the research and development of innovative drugs and external cooperation. The drug regulatory authorities will further optimize the review and approval process, support the introduction of original drugs for domestic production, and enhance the confidence of multinational enterprises in investing and developing in China; At the same time, relevant policies will be continuously improved to support and guide domestic enterprises, research and development institutions, etc. to increase the research and development of innovative drugs and high-quality generic drugs, and actively participate in competition in both domestic and ...
- Source: drugdu
- 170
- February 22, 2025
Two innovative medical devices have recently been approved

Recently, the National Medical Products Administration approved registration applications for two innovative medical devices, namely: the percutaneous glomerular filtration rate measurement device from Meidekang Company (hereinafter referred to as Meidekang) and the disposable balloon cryoablation catheter from Xinuopu Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as Xinuopu Medical). Meidekang: Combination of medicine and equipment to meet clinical needs MediBeacon was founded in 2012 and is dedicated to the research and development of medical optical diagnostic products, mainly involving fluorescent contrast agents and corresponding equipment. In 2019, East China Pharmaceutical invested 30 million dollars in Medecin, and obtained the exclusive commercialization rights of all Medecin products (including the follow-up development of new products) in 25 Asian countries or regions, including Chinese Mainland, Hong Kong, Taiwan, Singapore, and Malaysia, so as to layout the field of renal function monitoring. The approved percutaneous glomerular filtration rate measurement device – MediBeacon ® The ...
- Source: drugdu
- 114
- February 22, 2025
Urban cultural tourism and industrial development are gradually achieving two-way empowerment

Recently, the 9th Asian Winter Games came to a successful conclusion in Harbin, Heilongjiang Province. Ice and snow events have promoted the further popularization of ice and snow sports, and promoted the host city to continue and enhance the “Erbin” popularity of the previous ice and snow season. “Erbin” not only attracted domestic and foreign tourists to the ice and snow appointment, but also promoted the development of local enterprises. Harbin Pharmaceutical Group, a listed company, is one of the beneficiaries. Hu Xiaoping, secretary of the Party Committee of Harbin Pharmaceutical Group and chairman of Harbin Pharmaceutical Group, said in an interview with a reporter from Shanghai Securities News recently that the city’s attention and recognition have increased, talents have flocked in, and corporate development has benefited accordingly. “The city is popular, and the company will naturally benefit” Harbin Pharmaceutical Group is the first listed company in the pharmaceutical industry ...
- Source: drugdu
- 177
- February 22, 2025
Reaching $1.2 billion in overseas authorization, the old brand Shijiazhuang Pharmaceutical, which bets on innovative drugs, ushered in the harvest period

In recent years, antibody-drug conjugates (ADCs), known as “magic bullets”, have been very popular in the global pharmaceutical market. As a precision chemotherapy product, it is expected to replace the existing huge chemotherapy drug market. Especially in 2024, the research and development of ADC drugs ushered in an explosive period, and the number of research and development pipelines and related transactions grew rapidly. At present, this wave of enthusiasm has not cooled down. Before the market opened today (February 19), Shijiazhuang Pharmaceutical Group issued an announcement announcing that its subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as “Shijiazhuang Jushi”) and Radiance Biopharma, Inc. (hereinafter referred to as “Radiance Biopharma”) have entered into an exclusive licensing agreement for the development and commercialization of the Group’s recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate SYS 6005 in multiple regions. The specific regions include 13 regions ...
- Source: drugdu
- 128
- February 22, 2025
The “King of Dual-antibody drugs” strikes again

According to statistics, the global bispecific antibody market size will reach US$13 billion in 2024, among which the combined sales of cardunili and ivocizumab of Chinese pharmaceutical company Kangfang Bio are expected to exceed US$300 million, leading the trend of tumor immunotherapy bispecific antibodies. Recently, Kangfang Bio has once again expanded the application of bispecific antibodies to another explosive field – the autoimmune field. Kangfang Bio announced that its world’s first non-tumor bispecific antibody IL-4Rα/ST2 (AK139) IND has been accepted, targeting the large market of respiratory and skin autoimmune diseases. Challenge the 100 billion market Autoimmune diseases refer to diseases in which the body’s immune system malfunctions, causing the body to attack its own tissues. Currently, there are 100 different types of autoimmune diseases known, affecting about 7.6% to 9.4% of the world’s population. Among them, atopic dermatitis, asthma, COPD, psoriasis and other diseases have a prevalence of more than ...
- Source: drugdu
- 484
- February 22, 2025
Anlikang’s innovative drug ALK-N001 for injection clinical trial application accepted

On the evening of February 18, Zhejiang Anlikang Pharmaceutical Co., Ltd. issued an announcement stating that the company received the “Acceptance Notice” for the registration of domestically produced drug clinical trials for ALK-N001 for injection issued by the National Medical Products Administration. According to reports, ALK-N001 for injection is a globally innovative tumor microenvironment-activated small molecule conjugate drug. Anlikang has obtained the rights to develop the drug in the licensed area (mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, and Taiwan Province, China) through licensing. Preclinical study results show that the above-mentioned drug has a significant inhibitory effect on tumors in a variety of different tumor models and has good safety. It is a highly innovative and potential small molecule conjugate anti-tumor drug, which is expected to provide new treatment options for patients with advanced solid tumors. https://finance.eastmoney.com/a/202502183322572549.html
- Source: drugdu
- 224
- February 22, 2025
Seizing the opportunity of the Chinese market, multinational pharmaceutical companies saw revenue growth last year

Recently, the “report cards” of multinational pharmaceutical companies in 2024 have been released one after another. Overall, the leading multinational pharmaceutical companies have shown major trends such as revenue growth, significant volume growth of innovative products, and accelerated development of precise mergers and acquisitions. As one of the important pharmaceutical markets in the world, the Chinese market remains the focus of competition among major pharmaceutical companies. “Drug King” Competition According to the performance announced by multinational pharmaceutical companies, Johnson & Johnson ranked first with a total revenue of US$88.821 billion, and Roche, Merck, and Pfizer ranked second, third, and fourth with revenues of more than US$60 billion, respectively. AbbVie, AstraZeneca, and Novartis followed closely behind, with revenues exceeding US$50 billion. Bristol-Myers Squibb (BMS), Eli Lilly, Sanofi, Novo Nordisk, and GlaxoSmithKline all had revenues of more than US$40 billion. In the competition among multinational pharmaceutical companies, annual sales of tens of ...
- Source: drugdu
- 384
- February 21, 2025
Can Chengda Bio turn the tide?

Recently, Chengda Bio issued an announcement that its actual controller is intended to be changed from the State-owned Assets Supervision and Administration Commission of the People’s Government of Liaoning Province (hereinafter referred to as “Liaoning Provincial SASAC”) to no actual controller. Behind this is that Shaoguan Gaoteng became the controlling shareholder of Liaoning Chengda through the board of directors election, and indirectly controlled 54.67% of Chengda Bio’s equity through Liaoning Chengda. Shaoguan Gaoteng is a wholly-owned subsidiary of Guangdong Private Investment Co., Ltd. (hereinafter referred to as “Guangdong Private Investment”), and there is no actual controller after the equity structure is penetrated. At the same time, Chengda Bio also issued a tender offer announcement. The tender offerer is Shaoguan Gaoteng, which will acquire the unrestricted tradable shares held by all other shareholders of Chengda Bio except Liaoning Chengda, and will not terminate Chengda Bio’s listing status. The tender offer price ...
- Source: drugdu
- 216
- February 21, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.